BackBionano Genomics Overview

Bionano Genomics Accounts Payable

Track Bionano Genomics's accounts payable ($4.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$4.56M
26.94% YoYΔ $-1.68M vs prior year quarter

Peer trimmed avg / median

Loading

Bionano Genomics Accounts Payable History

Loading

Bionano Genomics vs. peers: Accounts Payable Comparison

Loading

Bionano Genomics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bionano Genomics (BNGO) FAQ

As of the most recent data (June 2026), BNGO shows a accounts payable of $4.6M. That compares with $6.2M in the prior-year period — down 26.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BNGO's accounts payable is now $4.6M (was $6.2M) — a 26.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bionano Genomics is outperforming or lagging.

Tracking BNGO's accounts payable over time shows whether Bionano Genomics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.6M That compares with $6.2M in the prior-year period — down 26.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Bionano Genomics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $4.6M) with ownership activity and broader fundamentals.

Bionano Genomics's accounts payable is $4.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.